GLP-1受容体作動薬の世界市場

GLP-1受容体作動薬の世界市場は2030年までに1,374億米ドルに到達

2024年に519億米ドルと推定されるGLP-1受容体作動薬の世界市場は、2024年から2030年にかけてCAGR 17.6%で成長し、2030年には1,374億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるオゼンピックは、CAGR19.2%を記録し、分析期間終了時には454億米ドルに達すると予想されます。Trulicityセグメントの成長率は、分析期間中CAGR 18.8%と推定されます。

米国市場は推定141億米ドル、中国はCAGR23.4％で成長予測

米国のGLP-1受容体作動薬市場は2024年に141億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに308億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは23.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、それぞれ分析期間中に12.9%と16.0%のCAGRで成長すると予測されています。欧州では、ドイツがCAGR約14.1%で成長すると予測されています。

世界のGLP-1受容体作動薬市場- 主要動向と促進要因のまとめ

GLP-1受容体作動薬が糖尿病・肥満治療に変革をもたらす理由とは？

グルカゴン様ペプチド-1（GLP-1）受容体作動薬は、2型糖尿病および肥満症の画期的な治療薬として登場し、従来の治療薬と比較して優れた血糖コントロールと体重減少効果をもたらしています。これらの注射薬や経口薬は、血糖値を調節し、インスリン分泌を促進し、胃排出を遅らせるホルモンであるGLP-1の作用を模倣し、糖代謝の改善と食欲抑制をもたらします。世界的に糖尿病と肥満の有病率が上昇する中、GLP-1受容体作動薬は現代の代謝疾患管理の要となっています。

同市場では、週1回投与製剤、併用療法、経口GLP-1受容体作動薬の導入など、患者のコンプライアンスと治療効果を向上させる大きな進歩が見られます。製薬会社はGLP-1薬の治療用途の拡大に多額の投資を行っており、心血管疾患、神経変性疾患、非アルコール性脂肪性肝疾患（NAFLD）における可能性を模索しています。ヘルスケアプロバイダーが効果的かつ長期的な治療オプションを優先する傾向が強まる中、GLP-1受容体作動薬に対する需要は拡大し続けています。

GLP-1受容体作動薬の需要を牽引している患者集団と治療領域は？

GLP-1受容体作動薬の主要市場は2型糖尿病患者であり、低血糖のリスクを最小限に抑えながら優れた血糖コントロールを提供します。GLP-1受容体作動薬には体重減少を促進する作用があることから、肥満治療薬としても注目されており、規制当局の承認により、糖尿病治療以外の用途にも使用されるようになっています。臨床試験では、肥満患者において有意な体重減少が証明されており、GLP-1受容体作動薬は体重管理のための主要な薬理学的解決策と位置づけられています。

GLP-1受容体作動薬は、糖尿病や肥満以外にも、心血管疾患予防におけるGLP-1受容体作動薬の役割についても研究が進められており、高リスク患者における主要有害心血管イベント（MACE）の減少が示されています。さらに、アルツハイマー病などの神経変性疾患の治療においても、GLP-1受容体作動薬が神経保護作用を示す可能性が検討されています。GLP-1受容体作動薬が多機能治療薬として認知されつつあることで、多様な治療領域で市場の可能性が広がっています。

GLP-1医薬品開発における最新の技術革新とは？

製薬業界は、有効性、利便性、患者のアドヒアランスの向上に重点を置き、医薬品開発において大きな進歩を遂げてきました。最も注目すべき技術革新の一つは、経口GLP-1受容体作動薬の導入であり、注射の必要性をなくし、より幅広い患者層が治療にアクセスできるようになりました。さらに、週1回投与や二剤併用療法などの徐放性製剤により、治療のアドヒアランスが向上し、代謝改善効果が長期間持続するようになりました。

もう一つの主な発展は、二重または三重の受容体活性を有するGLP-1受容体作動薬の開発であり、複数の代謝経路を標的としてグルコースコントロールと体重減少を強化します。AI主導の創薬により、薬物動態と安全性プロファイルが改善された新規GLP-1アナログの同定も加速しています。さらに、コネクテッドインスリンペンやリアルタイムのグルコースモニタリングなどのデジタルヘルスソリューションの統合は、個別化された治療推奨を提供することにより、GLP-1治療の有効性を高めています。これらの技術革新は、代謝性疾患管理の将来を形成し、GLP-1受容体作動薬をより効果的で利用しやすいものにしています。

GLP-1受容体作動薬市場の成長を促進している要因は？

GLP-1受容体作動薬市場の成長は、糖尿病や肥満の世界の有病率の上昇、治療用途の拡大、薬剤製剤の進歩など、いくつかの要因によってもたらされます。GLP-1受容体作動薬が効果的な体重管理ソリューションとして認知されるようになったことで、糖尿病患者以外にも広く採用されるようになりました。さらに、経口薬や二重拮抗薬などの新しい製剤に対する規制当局の承認が、市場の成長を強化しています。

製薬業界による代謝性疾患研究への投資と次世代GLP-1受容体作動薬の市場開拓が、市場拡大にさらに拍車をかけています。また、肥満治療を支援する保険適用や償還政策も、GLP-1治療薬への患者のアクセス拡大に一役買っています。さらに、デジタルヘルス・ソリューションとAI主導の精密医療の統合により治療成績が最適化され、GLP-1受容体作動薬が代謝性疾患の管理に好ましい選択肢となっています。革新的で効果的な治療に対する需要が高まり続ける中、GLP-1受容体作動薬市場は力強く持続的な成長が見込まれます。

セグメント

製品タイプ（Ozempic、Trulicity、Mounjaro、Wegovy、Rybelsus、Saxenda、Victoza、Zepbound、その他製品）、投与経路（非経口、経口）、流通チャネル（病院薬局流通チャネル、小売薬局流通チャネル、オンライン薬局流通チャネル）、用途（2型糖尿病用途、肥満症用途）

調査対象企業の例

• Amgen Inc.
• Ascendis Pharma A/S
• AstraZeneca
• BioAtla, Inc.
• Boehringer Ingelheim International GmbH
• Eli Lilly and Company
• Genentech, Inc.
• Hansoh Pharmaceutical Group
• ImCyse SA
• Innovent Biologics, Inc.
• Lexicon Pharmaceuticals
• Metsera, Inc.
• Novo Nordisk A/S
• Orgenesis Inc.
• PegBio Co., Ltd.
• Pfizer Inc.
• Roche Holding AG
• Sanofi
• The United Laboratories International Holdings Limited
• Viking Therapeutics, Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global GLP-1 Receptor Agonist Market to Reach US$137.4 Billion by 2030

The global market for GLP-1 Receptor Agonist estimated at US$51.9 Billion in the year 2024, is expected to reach US$137.4 Billion by 2030, growing at a CAGR of 17.6% over the analysis period 2024-2030. Ozempic, one of the segments analyzed in the report, is expected to record a 19.2% CAGR and reach US$45.4 Billion by the end of the analysis period. Growth in the Trulicity segment is estimated at 18.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$14.1 Billion While China is Forecast to Grow at 23.4% CAGR

The GLP-1 Receptor Agonist market in the U.S. is estimated at US$14.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$30.8 Billion by the year 2030 trailing a CAGR of 23.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.9% and 16.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.1% CAGR.

Global GLP-1 Receptor Agonist Market - Key Trends & Drivers Summarized

Why Are GLP-1 Receptor Agonists Transforming Diabetes and Obesity Treatment?

Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a breakthrough treatment for type 2 diabetes and obesity, offering superior glycemic control and weight loss benefits compared to traditional therapies. These injectable and oral medications mimic the action of GLP-1, a hormone that regulates blood sugar levels, promotes insulin secretion, and slows gastric emptying, leading to improved glucose metabolism and appetite suppression. With the rising prevalence of diabetes and obesity worldwide, GLP-1 receptor agonists have become a cornerstone of modern metabolic disease management.

The market has seen significant advancements, including the introduction of once-weekly formulations, combination therapies, and oral GLP-1 receptor agonists, which have improved patient compliance and treatment efficacy. Pharmaceutical companies are investing heavily in expanding the therapeutic applications of GLP-1 drugs, exploring their potential in cardiovascular disease, neurodegenerative disorders, and non-alcoholic fatty liver disease (NAFLD). As healthcare providers increasingly prioritize effective and long-lasting treatment options, the demand for GLP-1 receptor agonists continues to grow.

Which Patient Populations and Therapeutic Areas Are Driving Demand for GLP-1 Receptor Agonists?

The primary market for GLP-1 receptor agonists is patients with type 2 diabetes, where these drugs offer superior blood sugar control while minimizing the risk of hypoglycemia. Given their ability to promote weight loss, these medications are also gaining traction in the treatment of obesity, with regulatory approvals expanding their use beyond diabetes management. Clinical trials have demonstrated significant weight reduction in obese patients, positioning GLP-1 receptor agonists as a leading pharmacological solution for weight management.

Beyond diabetes and obesity, research is exploring the role of GLP-1 receptor agonists in cardiovascular disease prevention, as these drugs have shown a reduction in major adverse cardiovascular events (MACE) in high-risk patients. Additionally, ongoing studies are investigating their potential in treating neurodegenerative disorders such as Alzheimer’s disease, where GLP-1 analogs may exhibit neuroprotective effects. The growing recognition of GLP-1 receptor agonists as a multi-functional therapy is expanding their market potential across diverse therapeutic areas.

What Are the Latest Technological Innovations in GLP-1 Drug Development?

The pharmaceutical industry has made significant strides in GLP-1 receptor agonist drug development, focusing on improving efficacy, convenience, and patient adherence. One of the most notable innovations is the introduction of oral GLP-1 receptor agonists, eliminating the need for injections and making treatment more accessible to a broader patient population. Additionally, extended-release formulations, such as once-weekly and dual-agonist therapies, have enhanced treatment adherence and provided prolonged metabolic benefits.

Another key advancement is the development of GLP-1 receptor agonists with dual or triple receptor activity, targeting multiple metabolic pathways to enhance glucose control and weight reduction. AI-driven drug discovery is also accelerating the identification of novel GLP-1 analogs with improved pharmacokinetics and safety profiles. Furthermore, the integration of digital health solutions, such as connected insulin pens and real-time glucose monitoring, is enhancing the effectiveness of GLP-1 therapy by providing personalized treatment recommendations. These innovations are shaping the future of metabolic disease management, making GLP-1 receptor agonists more effective and accessible.

What Factors Are Fueling the Growth of the GLP-1 Receptor Agonist Market?

The growth in the GLP-1 receptor agonist market is driven by several factors, including the rising global prevalence of diabetes and obesity, expanding therapeutic applications, and advancements in drug formulations. The increasing awareness of GLP-1 receptor agonists as an effective weight management solution has contributed to broader adoption beyond diabetic populations. Additionally, regulatory approvals for new formulations, including oral and dual-agonist therapies, have strengthened market growth.

The pharmaceutical industry’s investment in metabolic disease research and the development of next-generation GLP-1 receptor agonists have further fueled market expansion. Insurance coverage and reimbursement policies supporting obesity treatment have also played a role in increasing patient access to GLP-1 therapies. Furthermore, the integration of digital health solutions and AI-driven precision medicine is optimizing treatment outcomes, making GLP-1 receptor agonists a preferred choice for managing metabolic disorders. As demand for innovative and effective treatments continues to rise, the GLP-1 receptor agonist market is expected to experience strong and sustained growth.

SCOPE OF STUDY:

The report analyzes the GLP-1 Receptor Agonist market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound, Other Products); Route of Administration (Parenteral, Oral); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel); Application (Type 2 Diabetes Mellitus Application, Obesity Application)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Amgen Inc.
• Ascendis Pharma A/S
• AstraZeneca
• BioAtla, Inc.
• Boehringer Ingelheim International GmbH
• Eli Lilly and Company
• Genentech, Inc.
• Hansoh Pharmaceutical Group
• ImCyse SA
• Innovent Biologics, Inc.
• Lexicon Pharmaceuticals
• Metsera, Inc.
• Novo Nordisk A/S
• Orgenesis Inc.
• PegBio Co., Ltd.
• Pfizer Inc.
• Roche Holding AG
• Sanofi
• The United Laboratories International Holdings Limited
• Viking Therapeutics, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • GLP-1 Receptor Agonist - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Prevalence of Type 2 Diabetes and Obesity Drives Demand for GLP-1 Receptor Agonist Therapies
  • Strong Clinical Evidence Supporting Weight Loss Benefits Strengthens Market Expansion Beyond Diabetes
  • FDA Approvals for New Indications and Weekly Dosing Regimens Accelerate Patient Adoption
  • Growing Interest in Cardiovascular Risk Reduction Enhances Therapeutic Scope of GLP-1 Drugs
  • Pharma Investment in Oral and Long-Acting Formulations Boosts Convenience and Compliance
  • Expansion of Reimbursement Programs and Insurance Coverage Supports Market Accessibility
  • High Patient Awareness and Direct-to-Consumer Marketing Fuel Demand for Branded GLP-1 Therapies
  • Rising Use in Medically Supervised Weight Management Programs Drives Volume Growth
  • Ongoing Innovation in Dual and Triple Agonists Enhances Competitive Differentiation
  • M&A Activity and Strategic Alliances Among Biopharma Companies Accelerate Pipeline Expansion
  • Shift Toward Personalized Medicine and Biomarker-Based Therapies Opens Niche Treatment Segments
  • Clinical Trials Exploring GLP-1 Role in NAFLD and NASH Unlock Future Market Opportunities
  • Epidemiological Transition in Developing Markets Expands Growth Potential in Asia and Latin America
  • Growing Telehealth and Digital Prescription Platforms Boost Accessibility to GLP-1 Therapies
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World GLP-1 Receptor Agonist Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for GLP-1 Receptor Agonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for GLP-1 Receptor Agonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Ozempic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Ozempic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Ozempic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Trulicity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Trulicity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Trulicity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Mounjaro by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Mounjaro by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Mounjaro by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Wegovy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Wegovy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Wegovy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Rybelsus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Rybelsus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Rybelsus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Saxenda by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Saxenda by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Saxenda by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Victoza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Victoza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Victoza by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Zepbound by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Zepbound by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Zepbound by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Hospital Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Online Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Type 2 Diabetes Mellitus Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Type 2 Diabetes Mellitus Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Obesity Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Obesity Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Obesity Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 53: USA Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: USA 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 65: Canada Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Canada 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 74: Canada Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Canada 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• JAPAN
  • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 77: Japan Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Japan 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Japan 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Japan 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 86: Japan Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Japan Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Japan 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• CHINA
  • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 89: China Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: China 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 92: China Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: China 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 95: China Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: China 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 98: China Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: China Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: China 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• EUROPE
  • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 101: Europe Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for GLP-1 Receptor Agonist by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for GLP-1 Receptor Agonist by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Europe 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Europe 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Europe 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 113: Europe Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Europe 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• FRANCE
  • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 116: France Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: France 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 119: France Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: France 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 122: France Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: France 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 125: France Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: France Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: France 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• GERMANY
  • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 128: Germany Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Germany 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 131: Germany Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Germany 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 134: Germany Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Germany 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 137: Germany Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Germany Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Germany 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 140: Italy Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Italy 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 143: Italy Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Italy 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 146: Italy Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Italy 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 149: Italy Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Italy Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Italy 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 152: UK Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: UK 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 155: UK Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: UK 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 158: UK Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: UK 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 161: UK Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: UK Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: UK 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 164: Spain Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Spain 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 167: Spain Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Spain 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 170: Spain Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Spain 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 173: Spain Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Spain Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Spain 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 176: Russia Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Russia 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 179: Russia Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Russia 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 182: Russia Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Russia 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 185: Russia Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Russia Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Russia 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Europe Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Europe 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for GLP-1 Receptor Agonist by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 15-Year Perspective for GLP-1 Receptor Agonist by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Asia-Pacific 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• AUSTRALIA
  • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 215: Australia Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Australia 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 218: Australia Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Australia 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 221: Australia Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Australia 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 224: Australia Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Australia Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Australia 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• INDIA
  • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 227: India Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: India 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 230: India Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: India 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 233: India Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: India 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 236: India Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: India Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: India 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: South Korea 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: South Korea 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: South Korea 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 248: South Korea Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: South Korea Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: South Korea 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Asia-Pacific Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Rest of Asia-Pacific 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for GLP-1 Receptor Agonist by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Latin America 15-Year Perspective for GLP-1 Receptor Agonist by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Latin America 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Latin America 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Latin America 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Latin America Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Latin America 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Argentina 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Argentina 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Argentina 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 287: Argentina Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Argentina Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Argentina 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Brazil 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Brazil 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Brazil 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 299: Brazil Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Brazil Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Brazil 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Mexico 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Mexico 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Mexico 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 311: Mexico Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Mexico Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Mexico 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Rest of Latin America Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Rest of Latin America 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for GLP-1 Receptor Agonist by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Middle East 15-Year Perspective for GLP-1 Receptor Agonist by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Middle East 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Middle East 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Middle East 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Middle East Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Middle East 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 341: Iran Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Iran 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 344: Iran Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Iran 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 347: Iran Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Iran 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 350: Iran Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Iran Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Iran 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 353: Israel Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Israel 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 356: Israel Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Israel 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 359: Israel Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Israel 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 362: Israel Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Israel Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Israel 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Saudi Arabia Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: Saudi Arabia 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 377: UAE Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: UAE 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 380: UAE Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: UAE 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 383: UAE Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: UAE 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 386: UAE Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: UAE Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: UAE 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Rest of Middle East Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Rest of Middle East 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
• AFRICA
  • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 401: Africa Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 403: Africa 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
  • TABLE 404: Africa Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 406: Africa 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • TABLE 407: Africa Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 409: Africa 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 410: Africa Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Africa Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 412: Africa 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030

IV. COMPETITION